CD274 and non-small cell lung carcinoma: The main advantage of this research is to identify potential factors that may influence the therapeutic outcomes observed in advanced NSCLC patients with negative driver mutations when treated with a combination of anlotinib and PD-1/PD-L1 inhibitors.